Global Lung Cancer Surgery Market Size By Type (Surgical Instruments, Monitoring And Visualization System), By Application (Lobectomy, Removal Of Sleeve), By Region, And Segment Forecasts, 2023 to 203...

The Global Lung Cancer Surgery Market was valued at USD 4.7 billion in 2023 and is projected to reach USD 7.6 billion by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. The rising prevalence of lung cancer globally, growing awareness about early cancer diagnosis, advancements in surgical techniques, and increased healthcare spending are the primary drivers for market growth. Lung cancer remains the leading cause of cancer-related deaths worldwide, which has resulted in an urgent demand for improved surgical outcomes, minimally invasive procedures, and robotic-assisted surgeries, further fueling market expansion.

Drivers:

1. Rising Prevalence of Lung Cancer:

The global surge in lung cancer incidence, particularly among aging populations and in regions with high smoking rates, continues to drive demand for surgical interventions as part of comprehensive treatment plans.

2. Technological Advancements in Surgical Techniques:

Innovations such as video-assisted thoracoscopic surgery (VATS), robotic surgery, and enhanced imaging-guided techniques are improving surgical precision and patient recovery rates, making lung cancer surgery safer and more effective.

3. Growing Demand for Minimally Invasive Procedures:

Patients and healthcare providers are increasingly favoring minimally invasive surgical options due to reduced postoperative complications, shorter hospital stays, and faster recovery.

Restraints:

1. High Cost of Surgery and Robotic Systems:

The high cost associated with lung cancer surgeries, especially robotic-assisted procedures, limits accessibility in low- and middle-income countries, posing a barrier to widespread adoption.

2. Postoperative Complications and Comorbidities:

Patients undergoing lung cancer surgery are at risk of severe postoperative complications, especially those with underlying conditions like COPD or cardiovascular issues, potentially deterring surgical decisions.

Opportunity:

1. Expanding Healthcare Infrastructure in Emerging Markets:

Rising investments in healthcare infrastructure, particularly across Asia-Pacific and Latin America, are creating significant opportunities for growth. These regions are witnessing increasing adoption of advanced surgical procedures and diagnostics.

2. Integration of AI and Robotics in Surgery:

The use of artificial intelligence in surgical planning and the expansion of robotic platforms offer opportunities to enhance accuracy, reduce operative time, and improve patient outcomes, fueling further innovation in the field.

Market by System Type Insights:

The lobectomy segment held the largest share in 2023, accounting for over 45% of the global market. This dominance is attributed to lobectomy being the most common and standard surgical approach for non-small cell lung cancer. Meanwhile, segmentectomy and wedge resection procedures are gaining traction due to their effectiveness in early-stage cancers and reduced impact on pulmonary function, especially among elderly patients.

Market by End-use Insights:

Hospitals accounted for the largest end-use segment in 2023, representing over 60% of total revenue. The presence of multidisciplinary oncology departments, availability of advanced surgical infrastructure, and the growing number of lung cancer surgeries performed annually contribute to this segment's dominance. Ambulatory surgical centers are expected to grow at a significant pace due to faster patient turnover and increasing preference for outpatient procedures.

Market by Regional Insights:

North America dominated the global lung cancer surgery market in 2023, driven by a well-established healthcare system, higher adoption of advanced surgical technologies, and strong reimbursement policies. Asia-Pacific is anticipated to exhibit the highest CAGR during the forecast period, owing to the rising cancer burden, increasing surgical capacity, and growing government focus on healthcare expansion in countries such as China and India.

Competitive Scenario:

Key players in the Global Lung Cancer Surgery Market include Johnson & Johnson Services, Inc., Intuitive Surgical Inc., Medtronic plc, Olympus Corporation, Teleflex Incorporated, Siemens Healthineers, Accuray Incorporated, and B. Braun Melsungen AG. These companies are investing heavily in R&D, expanding their surgical portfolios, and leveraging partnerships to enhance their geographic reach and technological capabilities.

Scope of Work – Global Lung Cancer Surgery Market

Report Metric Details

Market Size (2023) USD 4.7 billion

Projected Market Size (2031) USD 7.6 billion

CAGR (2023-2031) 6.3%

Market Segments By Procedure Type (Lobectomy, Segmentectomy, Pneumonectomy), End-use (Hospitals, Ambulatory Surgical Centers), Region

Growth Drivers Rising incidence of lung cancer, advancements in surgical technology, demand for minimally invasive procedures

Opportunities AI and robotic integration in surgery, growth in emerging healthcare markets

Key Market Developments:

2023: Intuitive Surgical introduced an updated version of its da Vinci robotic surgical system with AI-enhanced surgical precision tailored for thoracic procedures.

2024: Medtronic announced a strategic partnership with a major oncology center in India to expand access to VATS and robotic lung cancer surgeries.

2025: Johnson & Johnson acquired a surgical imaging startup to bolster its lung cancer surgery portfolio with real-time, image-guided navigation systems.